Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
information fournie par Boursorama CP 09/01/2026 à 08:00
Ajouter Boursorama à vos sources

TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses

Results reinforce TG4050 potential as an individualized cancer immunotherapy


Strasbourg, France, January 9, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the preprint publication on medRxiv of a comprehensive analysis of both the clinical and translational data from the Phase I part of its randomized Phase I/II trial of TG4050, an individualized neoantigen therapeutic vaccine (INTV).
The manuscript is now available on medRxiv - a preprint platform that enables early scientific visibility by sharing research ahead of journal peer review.
In parallel, the article has been submitted to a peer-reviewed journal and is currently under evaluation.

.../...

Valeurs associées

TRANSGENE
0,8540 EUR Euronext Paris -0,12%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
Pétrole Brent
99,43 -0,59%
CAC 40
8 154,91 +0,20%
HAFFNER ENERGY
0,637 +20,64%
2CRSI
29,36 +2,80%
VUSION
133 +13,68%
Chargement...

Pages les plus populaires

L'offre BoursoBank